Joint Mexican position document on the treatment of atrial fibrillation

Abstract Atrial fibrillation (AF) is a frequent arrhythmia; its prevalence is near 2% in the general population; in Mexico, more than one-half million people are affected. AF needs to be considered as a public health problem. Because AF is an independent risk factor associated with mortality, due to embolic events, heart failure, or sudden death; early diagnosis is of utmost importance. In unstable patients with a recent onset of AF, electrical cardioversion should be practiced. In stable patients, once thromboembolic measures have been taken, it is necessary to assess whether it is reasonable to administer an antiarrhythmic drug to restore sinus rhythm or performed electrical cardioversion. For recidivating cases of paroxysmal and persistent presentation, the most effective strategy is performed pulmonary vein isolation with either radiofrequency or cryoballoon energy. Permanent AF is that in which recovery of sinus rhythm is not possible, the distinguishing feature of this phase is the uncontrollable variability of the ventricular frequency and could be treated pharmacologically with atrioventricular (AV) nodal blockers or with a VVIR pacemaker plus AV nodal ablation. The presence of AF has long been associated with the development of cerebral and systemic (pulmonary, limb, coronary, renal, and visceral) embolism. The prevention of embolisms in “valvular” AF should perform with Vitamin K antagonists (VKA). For patients with AF not associated with mitral stenosis or a mechanical valve prosthesis, a choice can be made between anticoagulant drugs, VKA, or direct oral anticoagulants. Antiplatelet agents have the weakest effect in preventing embolism.

Saved in:
Bibliographic Details
Main Authors: Rodríguez-Diez,Gerardo, Márquez,Manlio F., Iturralde-Torres,Pedro, Molina-Fernández de L.,Luis G., Pozas-Garza,Gerardo, Cordero-Cabra,Alejandro, Rojel-Martínez,Ulises
Format: Digital revista
Language:English
Published: Instituto Nacional de Cardiología Ignacio Chávez 2020
Online Access:http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-99402020000100069
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1405-99402020000100069
record_format ojs
spelling oai:scielo:S1405-994020200001000692020-10-21Joint Mexican position document on the treatment of atrial fibrillationRodríguez-Diez,GerardoMárquez,Manlio F.Iturralde-Torres,PedroMolina-Fernández de L.,Luis G.Pozas-Garza,GerardoCordero-Cabra,AlejandroRojel-Martínez,Ulises Atrial fibrillation Drug treatment Tromboprofilaxis Cryoballoon ablation Radiofrequency ablation Abstract Atrial fibrillation (AF) is a frequent arrhythmia; its prevalence is near 2% in the general population; in Mexico, more than one-half million people are affected. AF needs to be considered as a public health problem. Because AF is an independent risk factor associated with mortality, due to embolic events, heart failure, or sudden death; early diagnosis is of utmost importance. In unstable patients with a recent onset of AF, electrical cardioversion should be practiced. In stable patients, once thromboembolic measures have been taken, it is necessary to assess whether it is reasonable to administer an antiarrhythmic drug to restore sinus rhythm or performed electrical cardioversion. For recidivating cases of paroxysmal and persistent presentation, the most effective strategy is performed pulmonary vein isolation with either radiofrequency or cryoballoon energy. Permanent AF is that in which recovery of sinus rhythm is not possible, the distinguishing feature of this phase is the uncontrollable variability of the ventricular frequency and could be treated pharmacologically with atrioventricular (AV) nodal blockers or with a VVIR pacemaker plus AV nodal ablation. The presence of AF has long been associated with the development of cerebral and systemic (pulmonary, limb, coronary, renal, and visceral) embolism. The prevention of embolisms in “valvular” AF should perform with Vitamin K antagonists (VKA). For patients with AF not associated with mitral stenosis or a mechanical valve prosthesis, a choice can be made between anticoagulant drugs, VKA, or direct oral anticoagulants. Antiplatelet agents have the weakest effect in preventing embolism.info:eu-repo/semantics/openAccessInstituto Nacional de Cardiología Ignacio ChávezArchivos de cardiología de México v.90 n.1 20202020-03-01info:eu-repo/semantics/articletext/htmlhttp://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-99402020000100069en10.24875/acme.m20000096
institution SCIELO
collection OJS
country México
countrycode MX
component Revista
access En linea
databasecode rev-scielo-mx
tag revista
region America del Norte
libraryname SciELO
language English
format Digital
author Rodríguez-Diez,Gerardo
Márquez,Manlio F.
Iturralde-Torres,Pedro
Molina-Fernández de L.,Luis G.
Pozas-Garza,Gerardo
Cordero-Cabra,Alejandro
Rojel-Martínez,Ulises
spellingShingle Rodríguez-Diez,Gerardo
Márquez,Manlio F.
Iturralde-Torres,Pedro
Molina-Fernández de L.,Luis G.
Pozas-Garza,Gerardo
Cordero-Cabra,Alejandro
Rojel-Martínez,Ulises
Joint Mexican position document on the treatment of atrial fibrillation
author_facet Rodríguez-Diez,Gerardo
Márquez,Manlio F.
Iturralde-Torres,Pedro
Molina-Fernández de L.,Luis G.
Pozas-Garza,Gerardo
Cordero-Cabra,Alejandro
Rojel-Martínez,Ulises
author_sort Rodríguez-Diez,Gerardo
title Joint Mexican position document on the treatment of atrial fibrillation
title_short Joint Mexican position document on the treatment of atrial fibrillation
title_full Joint Mexican position document on the treatment of atrial fibrillation
title_fullStr Joint Mexican position document on the treatment of atrial fibrillation
title_full_unstemmed Joint Mexican position document on the treatment of atrial fibrillation
title_sort joint mexican position document on the treatment of atrial fibrillation
description Abstract Atrial fibrillation (AF) is a frequent arrhythmia; its prevalence is near 2% in the general population; in Mexico, more than one-half million people are affected. AF needs to be considered as a public health problem. Because AF is an independent risk factor associated with mortality, due to embolic events, heart failure, or sudden death; early diagnosis is of utmost importance. In unstable patients with a recent onset of AF, electrical cardioversion should be practiced. In stable patients, once thromboembolic measures have been taken, it is necessary to assess whether it is reasonable to administer an antiarrhythmic drug to restore sinus rhythm or performed electrical cardioversion. For recidivating cases of paroxysmal and persistent presentation, the most effective strategy is performed pulmonary vein isolation with either radiofrequency or cryoballoon energy. Permanent AF is that in which recovery of sinus rhythm is not possible, the distinguishing feature of this phase is the uncontrollable variability of the ventricular frequency and could be treated pharmacologically with atrioventricular (AV) nodal blockers or with a VVIR pacemaker plus AV nodal ablation. The presence of AF has long been associated with the development of cerebral and systemic (pulmonary, limb, coronary, renal, and visceral) embolism. The prevention of embolisms in “valvular” AF should perform with Vitamin K antagonists (VKA). For patients with AF not associated with mitral stenosis or a mechanical valve prosthesis, a choice can be made between anticoagulant drugs, VKA, or direct oral anticoagulants. Antiplatelet agents have the weakest effect in preventing embolism.
publisher Instituto Nacional de Cardiología Ignacio Chávez
publishDate 2020
url http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1405-99402020000100069
work_keys_str_mv AT rodriguezdiezgerardo jointmexicanpositiondocumentonthetreatmentofatrialfibrillation
AT marquezmanliof jointmexicanpositiondocumentonthetreatmentofatrialfibrillation
AT iturraldetorrespedro jointmexicanpositiondocumentonthetreatmentofatrialfibrillation
AT molinafernandezdelluisg jointmexicanpositiondocumentonthetreatmentofatrialfibrillation
AT pozasgarzagerardo jointmexicanpositiondocumentonthetreatmentofatrialfibrillation
AT corderocabraalejandro jointmexicanpositiondocumentonthetreatmentofatrialfibrillation
AT rojelmartinezulises jointmexicanpositiondocumentonthetreatmentofatrialfibrillation
_version_ 1756226638607024128